Skip to main content
OpenTrials
Completed

NCT Number: NCT02531126

An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

The purpose of this study is to evaluate the long-term safety and efficacy of RPC1063 in participants with moderately to severely active ulcerative colitis. Only those participants who have previously participated in a trial of RPC1063, being either RPC01-3101 or completed at least 1 year of the open-label period of RPC01-202 will be eligible.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Local Institution - 152, Camperdown, New South Wales, Australia

Loading trial locations.

About this study

This is an extension study trial. Eligible participants from the RPC01-3101 and RPC01-202 trials were able to roll-over in this trial to receive study medication until March 2023 or until the Sponsor discontinues the development program, whichever comes first.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit: www.BMSStudyConnect.com

Inclusion criteria

  • Previously participated in a trial of RPC1063 and meets the criteria for participation in the open-label extension as outlined in the prior trial

Exclusion criteria

  • Receiving treatment with breast cancer resistance protein inhibitors
  • Clinically relevant cardiovascular conditions
  • Liver function impairment

Other protocol-defined inclusion/exclusion criteria apply

Treatment and study plan

RPC1063

Drug

Other names: Ozanimod

Primary outcomes

  1. Number of Participants Experiencing Treatment-Emergent Adverse Event (TEAEs)

    Time frame: From first dose to 90 days post last dose (Up to approximately 92 months)

    Number of participants experiencing TEAEs, Serious TEAEs, TEAEs leading to discontinuation and TEAEs of special interest. TEAE is defined as any event with an onset date on or after the first dose date, or any ongoing event on the first dose date that worsens in severity on or after the first dose date, and until 90 days following the last dose of treatment with the study drug.

Secondary outcomes

  1. Percentage of Participants With Clinical Remission

    Time frame: Week 46, 94, 142, 190, 238

    Clinical Remission is defined as Rectal bleeding subscore=0; stool frequency subscore <=1 (and a decrease of >=1 point from the baseline stool frequency subscore); and endoscopy subscore <=1.

    Rectal bleeding 0 = No blood seen Stool frequency 0 = Normal number of stools for this patient; 1 = 1 to 2 stools more than normal Endoscopy 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern, does not include friability).

  2. Percentage of Participants With Clinical Response

    Time frame: Week 46, 94, 142, 190, 238

    Clinical response is defined as reduction from baseline in the 9-point Mayo score of >=2 points and reduction from baseline in the 9-point Mayo score >=35%, and (reduction from baseline in the rectal bleeding subscore of >=1 point or a rectal bleeding subscore of <=1 point). 9 point Mayo score is defined as the sum of rectal bleeding subscore, stool frequency subscore, and the endoscopy subscore each ranging from (0=normal activity-3=worse activity) for a total score that ranges from 0 to 9 with higher score indicating worsening symptoms.

  3. Percentage of Participants With Endoscopic Improvement

    Time frame: Week 46, 94, 142, 190, 238

    Endoscopic Improvement is defined as endoscopy subscore of <=1 point. 0 = Normal or inactive disease;

    • = Mild disease (erythema, decreased vascular pattern, does not include friability)
    • = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions)
    • = Severe disease (spontaneous bleeding, ulceration)
  4. Percentage of Participants With Corticosteroid-free Remission

    Time frame: Week 46, 94, 142, 190, 238

    Corticosteroid-free remission is defined as clinical remission while off corticosteroids for ≥12 weeks. Clinical Remission is defined as Rectal bleeding subscore=0; stool frequency subscore <=1 (and a decrease of >=1 point from the baseline stool frequency subscore); and endoscopy subscore <=1.

    Rectal bleeding 0 = No blood seen Stool frequency 0 = Normal number of stools for this patient; 1 = 1 to 2 stools more than normal Endoscopy 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern, does not include friability).

  5. Percentage of Participants With Histologic Remission

    Time frame: Week 46, 94, 142, 190, 238

    Histologic remission is defined as Geboes index score < 2.0. The Geboes score is a validated histological grading system for UC that ranges from 0=no disease activity to 5=high disease activity.

  6. Percentage of Participants With Mucosal Healing

    Time frame: Week 46, 94, 142, 190, 238

    Mucosal Healing is defined as Endoscopy subscore of ≤ 1 point (0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern, does not include friability)) and a Geboes index score < 2.0 (The Geboes score is a validated histological grading system for UC that ranges from 0=no disease activity to 5=high disease activity.)

  7. Change From Baseline in Complete Mayo Score

    Time frame: Baseline, week 46, 94, 142, 190, 238, 286, 334, 382

    The Complete Mayo Score is a composite of four assessments, each rated from 0 to 3:

    • Stool frequency: (0 = Normal number of stools for this patient; 1 = 1 to 2 stools more than normal; 2 = 3 to 4 stools more than normal; 3 = 5 or more stools more than normal)
    • Rectal bleeding (0 = No blood seen; 1 = Streaks of blood with stool less than half the time; 2 = Obvious blood with stool most of the time; 3 = Blood alone passes)
    • endoscopy (0 = Normal or inactive disease; 1 = Mild disease; 2 = Moderate disease; 3 = Severe disease)
    • Physician's Global Assessment (0 = Normal; 1 = Mild disease; 2 = Moderate disease; 3 = Severe disease).

    The total score range is from 0-12, with higher score indicating worse disease activity. Baseline is the last measurement collected on or prior to the date of first dose in the 3102 OLE study.

  8. Change From Baseline in Partial Mayo Score

    Time frame: Baseline, week 46, 94, 142, 190, 238, 286, 334, 382

    The Partial Mayo Score is a composite of three assessments, each rated from 0 to 3:

    • Stool frequency: (0 = Normal number of stools for this patient; 1 = 1 to 2 stools more than normal; 2 = 3 to 4 stools more than normal; 3 = 5 or more stools more than normal)
    • Rectal bleeding (0 = No blood seen; 1 = Streaks of blood with stool less than half the time; 2 = Obvious blood with stool most of the time; 3 = Blood alone passes)
    • Physician's Global Assessment (0 = Normal; 1 = Mild disease; 2 = Moderate disease; 3 = Severe disease).

    The total score range is from 0-9, with higher score indicating worse disease activity. Baseline is the last measurement collected on or prior to the date of first dose in the 3102 OLE study.

  9. Change From Baseline in 9-Point Mayo Score

    Time frame: Baseline, week 46, 94, 142, 190, 238, 286, 334, 382

    The 9-point Mayo Score is a composite of three assessments, each rated from 0 to 3:

    • Stool frequency: (0 = Normal number of stools for this patient; 1 = 1 to 2 stools more than normal; 2 = 3 to 4 stools more than normal; 3 = 5 or more stools more than normal)
    • Rectal bleeding (0 = No blood seen; 1 = Streaks of blood with stool less than half the time; 2 = Obvious blood with stool most of the time; 3 = Blood alone passes)
    • Endoscopy (0 = Normal or inactive disease; 1 = Mild disease; 2 = Moderate disease; 3 = Severe disease) The total score range is from 0-9, with higher score indicating worse disease activity. Baseline is the last measurement collected on or prior to the date of first dose in the 3102 OLE study.
  10. Percentage of Participants Who Had Previously Received Anti-TNF Therapy With Clinical Remission

    Time frame: Week 46, 94, 142, 190, 238

    Clinical Remission is defined as Rectal bleeding subscore=0; stool frequency subscore <=1 (and a decrease of >=1 point from the baseline stool frequency subscore); and endoscopy subscore <=1.

    Rectal bleeding 0 = No blood seen Stool frequency 0 = Normal number of stools for this patient; 1 = 1 to 2 stools more than normal Endoscopy 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern, does not include friability).

  11. Percentage of Participants Who Had Previously Received Anti-TNF Therapy With Clinical Response

    Time frame: Week 46, 94, 142, 190, 238

    Clinical response is defined as reduction from baseline in the 9-point Mayo score of >=2 points and reduction from baseline in the 9-point Mayo score >=35%, and (reduction from baseline in the rectal bleeding subscore of >=1 point or a rectal bleeding subscore of <=1 point). 9 point Mayo score is defined as the sum of rectal bleeding subscore, stool frequency subscore, and the endoscopy subscore each ranging from (0=normal activity-3=worse activity) for a total score that ranges from 0 to 9 with higher score indicating worsening symptoms.

  12. Percentage of Participants Who Had Previously Received Anti-TNF Therapy With Endoscopic Improvement

    Time frame: Week 46, 94, 142, 190, 238

    Endoscopic Improvement is defined as endoscopy subscore of <=1 point. 0 = Normal or inactive disease;

    1 = Mild disease (erythema, decreased vascular pattern, does not include friability)

Sponsors and collaborators

Lead sponsor

Celgene

Industry

Registry information

Official study title

A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

Important dates

Study start
2015
Primary completion
2024
Study completion
2024
First posted
Aug 24, 2015
Registry last updated
Dec 31, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.